Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private

Enabling Oral Drug Delivery to Improve Patient Compliance March 28, 2019 Corporate Presentation Exhibit 99.1

Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward - looking statement s relate to the Company's product candidates, the expected timing of the resubmission of the NDA for TLANDO, FDA review process related to ou r resubmitted NDA for TLANDO , the expected timing of Phase 2 studies for LPCN 1144 and LPCN 1148, clinical and regulatory proc ess es and objectives, potential benefits of the Company's product candidates, intellectual property and related matters, all of which i nvo lve known and unknown risks and uncertainties. Actual results may differ materially from the forward - looking statements discussed in this pre sentation . Accordingly, the Company cautions investors not to place undue reliance on the forward - looking statements contained in, or made in connection with, this presentation . Several factors may affect the initiation and completion of clinical trials and studies, the potential advantages of the Company's product candidates and the Company's capital needs. The forward - looking statements contained in this presentation are qualified by the detailed discussion of risks and uncertainties set forth in the Company's annual report on For m 10 - K and other periodic reports filed by the Company with the Securities and Exchange Commission, all of which can be obtained on the Com pany's website at www.lipocine.com or on the SEC website at www.sec.gov . The forward - looking statements contained in this document represent the Company's estimates and assumptions only as of the date of this presentation and the Company undertakes no duty or obligation to update or revise publicly any forward - looking statements contained in this presentation as a result of new information, future events or changes in the Company's expectations. 2

Clinical Stage Biopharmaceutical Company Metabolic and Endocrine Focus 3 PRODUCT (Indication) PRE - CLINICAL PHASE 1 PHASE 2 PHASE 3 NDA LPCN 1144 (Oral Testosterone for NASH) Phase 2 Study in Biopsy Confirmed NASH LPCN 1148 (Oral Testosterone for NASH Cirrhosis) POC Study Planned TLANDO (Oral Testosterone for TRT) NDA Resubmission LPCN 1111 (Next Gen Oral Testosterone for TRT) Phase 2 Completed LPCN 1107 (Oral HPC for Prevention of PTB) EOP2 Completed Propriety Drug Delivery Platform

4 Targeted for Non - Alcoholic Steatohepatitis ("NASH") A silent killer that affects 30 million Americans 1 1. CNBC; published December 30, 2018

Non - Alcoholic Fatty Liver Disease ("NAFLD") No Approved Product for the Treatment of NASH 5 LFTs: Liver function test, especially Alaninine amino transferase (ALT) and Aspartame amino transferase (AST) NASH: Non - alcoholic Steatohepatitis, TG: Triglyceride Fatty liver is a reversible condition wherein large vacuoles of triglyceride (TG) fat accumulate in liver cells via the process of steatosis Healthy Liver Fatty Liver - TGs - LFTs - Liver fat NASH Liver - Steatosis - Ballooning - Inflammation - Fibrosis Cirrhotic Liver - Late stage of fibrosis Hepatocellular Carcinoma 20 - 30% US Adults 15 - 20% NAFLDs 10 - 20% NASH Eligible for Liver Transplantation

NASH Pathogenesis Risk Factors and Clinical Progression Lipid Metabolism Disorders Dyslipidemia Insulin resistance Obesity T2 diabetes Metabolic syndrome Inflammation Lipid peroxidation Mitochondrial dysfunction Oxidative stress Apoptosis Pro - inflammatory cytokine activation Fibrosis Scarring Advanced cell damage The removal of pro - fibrotic inputs or the strengthening of anti - fibrotic inputs is expected to stimulate scar resolution* Liver contains built - in mechanisms for scar resolution, but these become smothered or inactivated in the face of relentless damage* * Luc a Cordero - Espinoza and Meritxell Huch J Clin Invest. 2018;128(1):85 - 96. 6 5% liver fat accumulation

Clinical Relationship Between Testosterone and NAFLD Across the Full Disease Spectrum Hepatic Steatosis NASH Cirrhosis " Men with low testosterone are at high risk for NAFLD ." 1 Free T ( pg /mL) " Levels of free T decreased significantly with the increased incidence of lobular inflammation, hepatocyte ballooning, NAFLD activity score, and fibrosis." 2 "Low T levels in cirrhotic men are associated with the combined outcome of death or transplantation." 3 Free T ( pg /mL) 1 Kim et al, Gastroenterol 2012; 2 Sumida et al, Gastroenterol Hepatol 2015; 3 Sinclair et al, Liver Trans 2016; 7

LPCN 1144: Oral Testosterone Targeting The Full Spectrum of NASH Pathogenesis A Differentiated Oral NASH Therapy Candidate Well tolerated - suitable for chronic use Favorable benefits outside the liver Clinical Data to Advance in Phase 2 Testing Meaningful liver fat reductions as early as eight weeks and we believe the potential to improve upon longer treatment duration Substantial reductions in key elevated serum markers We believe there is potential for histological improvement in NASH patients 8

LPCN 1144: Multidimensional Mechanism of Action Across the Full Spectrum of NASH Pathogenesis Homeostasis Modifier 1, 2 Alter lipid, cholesterol, and glucose metabolism Reduce visceral abdominal fat Modify activity of hepatic lipase, and skeletal muscle/ adipose lipoprotein lipase Anti - inflammatory 2 / Antioxidant/Immuno - modulator 3 Restore mitochondrial turnover and normalizes oxygen consumption 4 Regeneration Booster 5,6 Stimulate satellite cells and myocyte precursor resulting in cell differentiation and myocyte proliferation 7 Increases circulating endothelial progenitor cells ("EPC") 8 Anabolic Agent 9 Increase muscle mass, bone density in men with liver disease 10 9 1. Shen and Shi, Int J Endocrinol, 2015; 2. Kelly and Jones, J Endocrinol, 2013 ; 3. Sinclair et al., J Gastroenterol Hepatol , 2015; 4. Linda Vignozzi et al., University of Florence, IT, unpublished, 2018; 5. A. Francavilla et al., Digest Dis Sci, 1989; 6. Vic et al., Hepatol 1982; 7. Sinha - Hikim et al., J Clin Endocrinol Metab , 2004; 8. Liao CH et al., Andrology, 2013. 9. Gentile MA et al., J Mol Endocrine, 2010; 10. Sinclair et al., J Gastroenterol Hepatol 2016;

LPCN 1144: A Differentiated Oral NASH Therapy Candidate Prodrug of Endogenous Testosterone Liver Fat Reduction and Key Serum Biomarkers Potential Favorable Benefits in Systems Outside the Liver Suitable for Chronic Use Over 40% relative mean liver fat reduction after 16 - weeks of treatment 48% of the treated NAFLD subjects had NAFLD resolution, defined as < 5% liver fat T therapy known to improve muscle mass, bone density, hemopoiesis, sexual/mood dysfunction Good GI tolerability No mean LDL increase No signs of nephrotoxicity No signs of skeletal fragility No signs of drug induced liver toxicity 10

LPCN 1144: Liver Fat Imaging Study ("LFS") Study Design and Baseline Liver Fat Subject Distribution 11 LFS was an open - label, multi - center single - arm 16 - week study (N=36) with LPCN 1144 in hypogonadal males LF = liver fat

LPCN 1144: Liver Fat Study Results Meaningful Relative Liver Fat % Change and Responder Rate 12 - 33% - 42% - 40% -60% -50% -40% -30% -20% -10% 0% BL 5% BL 8% BL 10% % Liver Fat CBL ( SEM) Mean Relative Liver Fat % Change 71% 80% 75% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% BL 5% BL 8% BL 10% % of Responders Responder Rate for Relative Liver Fat % Change* * Responder rate for relative change is % of patients with at least 30% for relative change from baseline.

100% of patients experiencing NAFLD resolution had at least 35% of relative liver fat reduction from baseline * Resolution of NAFLD is defined as when BL liver fat 5% is reduced to < 5% at EOS. 28% 48% 0% 10% 20% 30% 40% 50% Resolution of NAFLD % of Subjects Resolution of NAFLD* 8 Wks 16 Wks - 45% - 55% -60% -40% -20% 0% Patients with NAFLD Resolution Mean Relative Liver Fat % Change Mean Relative Liver Fat % Change 8 Wks 16 Wks LPCN 1144: Liver Fat Study Results Meaningful NAFLD Resolution and Corresponding Relative Liver Fat % Reduction 13

LPCN 1144: Liver Fat Study Results Liver Fat Based Subject Distribution at Each Visit 14 38% 32% 6% 24% Baseline Pre treatment 55% 18% 6% 21% 8 Week Treatment 65% 15% 12% 9% 16 Week Treatment LF < 5% (NAFLD Free) 5% LF < 8% 8% LF < 10% LF > 10% NAFLD Free NAFLD Free NAFLD Free Longer Therapy Improved Liver Fat Reductions and Proportion of Subjects with Disease Resolution N=34 N=33 N=34

LPCN 1144: Next Step Advancing Forward Initiate Phase 2 clinical study in biopsy confirmed NASH subjects - Study Design Three - arm, placebo controlled Biopsy confirmed F2/F3 NASH male hypogonadal subjects with NAS 4 Paired biopsy at baseline and EOS 36 - weeks duration - IND cleared by FDA 15

16 For Treatment of NASH Cirrhosis

LPCN 1148: Oral T for NASH Cirrhosis No FDA Approved Drugs - Transplant Only Cure Cirrhotic Liver US Prevalence Cirrhotic Patients Characteristics: Increased morbidity and mortality Symptoms of hypogonadism: hair distribution, anemia, sexual dysfunction, testicular atrophy, muscle wasting, fatigue, osteoporosis, gynecomastia Late stage symptoms: jaundice, pruritis, hepatic encephalopathy, ascites, anasarca, GI bleeding Estes C. et al., Hepatology, 2018;Yoon and Chen, National Institute on Alcohol Abuse and Alcoholism; surveillance report , 2 016 17 Among 2015 NASH population: Fibrosis grade 4 (cirrhosis) case: 1.3M Compensated cirrhosis 1.16M Decompensated cirrhosis: 134,400 In 2013, cirrhosis cause mortality was ~38,000 and consistently twice the rate in males as females **

Low Testosterone Increases Adverse Outcome in Male Cirrhotic Patients T Levels Fall Progressively with Increasing Disease Severity 1 Low T reported in up to 90% of NASH cirrhosis patients 2 and is a predictor of mortality 3 Low T associated with: - Increased risk of major infections, death and/ or transplantation rates 1 - Increased risk of for hepatic decompensation 4 - Worsening of sarcopenia 4 - Higher Child Pugh score grade 4 - Severity of portal hypertension and ascites grade 4 - Higher MELD score 5 1. Sinclair et al., Liver Transplantation, 2016 2. Kim et al., Male Hypogonadism , edrs : Winters and Huhtaniemi , 2017 3. Sinclair M. et al., J. of Gastro and Hepatology, 2015 4. Paternostro et al, Hepatol Res 2019; 5. Sinclair et.al, Liver international, 2016 18

LPCN 1148: NASH Cirrhosis Oral T Therapy Potentially help patients survive longer while waiting for a liver transplant T levels positively correlate with muscle mass in men and modulates bone density, hemoglobin production, insulin resistance, and immunity , commonly impaired in cirrhosis 1 Testosterone therapy increased muscle mass in men with Cirrhosis and low testosterone 2 Next Steps: Proof of Concept study in male NASH cirrhosis subjects 19 1. Sinclair M et al., J. of Gastro and Hepatology, 2016 2. Sinclair M et al., J. of Hepatology, 2016

20 Targeted for Testosterone Replacement Therapy Annual TRx ~7M

Issues with Current Non - oral TRT Options Black Box Warning - Secondary exposure to testosterone - Pulmonary oil micro embolism (POME) and anaphylaxis shock Inconvenient application or painful injection Poor persistence reflects need for oral - Average days on therapy is 100 days More than 50% of patients need dosage adjustment - Burdensome for patients due to multiple doctor visits Potential Barrier To Newly Diagnosed and Existing Patients 21

TLANDO : Potential First Oral Option Progressing to NDA Resubmission 22 Deficiency 1 Determine extent, if any, of ex vivo conversion of TU to T Deficiency 2 Characterize blood pressure effects of TLANDO for appropriate regulatory action Deficiency 3 Provide justification for non - applicability of Cmax based secondary endpoints Deficiency 4 Determine the appropriate stopping criteria that can identify patients who should discontinue NDA Resubmission 2Q 2019

TLANDO : Potential First Oral Option Profile Demonstrated Clinically with Target Label Regimen Met primary endpoint - 80% response rate in "worst - case analysis" vs. FDA requirement of 75% - Justification for non - applicability of Cmax based missed secondary endpoints Efficacy 591 subject exposure Well tolerated in 52 week exposure - AE profile comparable to active control, including GI - No cardiac, hepatic or drug related SAEs - No increase in mean BP with cuff measurements No apparent correlation of the observed Cmax excursions - ADRs, AEs, Meaningful changes in critical lab parameters Safety Preferred oral option - No risk of accidental T transference - Non - invasive - Less cumbersome - Less burdensome - Simpler to prescribe - Fewer doctor visits - Easier for patients to properly use Clear Benefits 23

Upcoming Milestones 24 Near Term Value Drivers Event Expected Timing TLANDO NDA Resubmission 2Q 2019 LPCN 1144 Phase 2 Study Start in Biopsy Confirmed NASH Patients 2H 2019

Key Financial Metrics 25 Stock Price, Market Cap, Cash Balance Ticker Symbol LPCN (Nasdaq Capital Market) Closing Stock Price (3/26/19) $2.19/share Market Capitalization (3/26/19) $52.3 million Cash Balance (12/31/18) $20.3 million* Bank Debt (12/31/18) $10.0 million * $5 M restricted

27 Targeted for pre - cirrhosis NASH

LPCN 1144: Additional Health Benefits Observed in Hypogonadal Subjects with Elevated ALT* SF - 36, Short Form - 36 (0 - 100); PDQ, Psychosexual Daily Questionnaire (0 - 7); * ALT > 40 U/L at Baseline in 52 week SOAR Trial (N=3 3) Mental Component Summary Mental Health Role Emotional Maintained Erection Sexual Activity Negative Mood Positive Mood Overall Sexual Desire -4 -2 0 2 4 6 8 Mean Change ( 95% CI) from Baseline SF - 36 PDQ 28

LPCN 1144: General Safety Well Tolerated Extensive clinical safety database with LPCN 1144 - 700+ subjects in 14 studies with up to 52 week exposure - No drug related SAEs - Safety profile well - characterized and demonstrated no unexpected risks - Good gastrointestinal tolerability with no signs of skeletal fragility or nephrotoxicity - No signs of drug induced liver enzyme toxicity, no deaths or MACE events 29

LPCN 1144: Gastrointestinal Safety Gastrointestinal Disorders 1% in SOAR Trial (52 Weeks) 0 5 10 15 % Subjects LPCN 1144 Topical T 30

LPCN 1144: Consistent Liver Function Improvement Across Studies* Effect Observed as Early as 3 Weeks - 17.4% - 10.3% - 5.1% - 9.6% - 18.8% - 13.2% - 10.1% - 18.5% -30% -25% -20% -15% -10% -5% 0% ALT AST ALP GGT Mean Change from BL ( SEM) SOAR (52 Week) 16-002 (3 Week) Mean BL (U/L) 53.6 55.6 32.0 32.6 74.0 75.5 53.6 57.9 LPCN 1144 Patients for ALT > 40 U/L at BL; SOAR ( NCT02081300), N=42, 16 - 002 (NCT03242590), N=13 ; 31

LPCN 1144: Oral T Appreciable % of Patients Experienced Normalization of ALT, GGT, TG, LDL - C, and Lp - PLA2 32 52% 31% 34% 56% 52% 0% 10% 20% 30% 40% 50% 60% ALT* GGT* TG* LDL-C* Lp-PLA2* % of Normalized Patients from Above - normal at Baseline Normalization of Biomarkers with LPCN 1144 N 42 36 73 16 25 BL 53.6 U/L 82.2 U/L 320 mg/dL 175 mg/dL 277 ng/mL * ALT, GGT, TG, LDL - C, and Lp - PLA2 normal range upper limit is 40 U/L, 49 U/L, 200 mg/dL, 160 mg/dL, and 235 ng/mL, respectively 52 Week SOAR Trial

52 Week SOAR Trial TG mean change post therapy in patients on oral T vs non - oral T therapy LPCN 1144: Oral T Unique TG Reduction Compared to Topical Gel 33 - 63.7 13.7 -80 -60 -40 -20 0 20 40 60 Mean BL = 320 mg/dL 323 mg/dL N = 73/210 34/104 LPCN 1144 Topical T Mean Change from Baseline (mg/ dL ) TG Mean Change after 52 Week for Patients with Above - normal TG* at BL 200 250 300 350 400 0 13 26 39 52 Mean Value for Patients with Above - normal at BL (mg/dL) Therapy Duration (Week) TG Mean Value for Patients with Above - normal TG* at BL during 52 Week Therapy LPCN 1144 Topical T * TG normal range in SOAR Trial: 45 - 200 mg/dL

52 Week SOAR Trial LPCN 1144: Oral T Unique Effects on Liver Compared to Topical Gel 34 - 4.8% 3.3% -10% -5% 0% 5% 10% Mean BL = 71.8 U/L 72.5 U/L LPCN 1144 Topical T Mean Change from Baseline ALP Mean Change after 52 Week - 19.5% 8.3% -30% -20% -10% 0% 10% 20% Mean BL = 30.3 nmol/L 30.4 nmol/L LPCN 1144 Topical T Mean Change from Baseline SHBG Mean Change after 52 Week

Hypogonadism Affects Up to 20 M American Men 1,2 36 Significant Number of Untreated Hypogonadal Males ~6M Men with diagnosed hypogonadism 3 2.2M Men currently being treated 4 700,000 New na ve patients each year 5 1. US Census data. http://www.infoplease.com/us/census/data/demographic.html. 2. Mulligan T, et al. Int J Clin Pract . 2006 Jul;60(7):762 - 9. 3. Araujo, et al. J Clin Endo Metabol 2007. 92(11):4241 - 7. 4. Symphony Healthcare 2014 for FDA Advisory Meeting. 5. IMS Health Sept 2015. Asymptomatic and/or Undiagnosed Hypogonadism 70% Diagnosed Untreated 19% 68% 32% Treated 11% Previously Treated Treatment Na ve

TLANDO : Patient Market Research Patient Enthusiasm Evident About Oral TRT 37 37 80% of interviewed TRT patients 30% 30% "Oral Form " 30% "It's not Gel", " Not Injection" " Ease of Use" Likely or Highly Likely to Ask Physician to Prescribe TLANDO What Most Like About TLANDO? Other TLANDO generates strong patient enthusiasm among current and prior TRT users - Oral administration and lack of transference viewed as key benefits For transdermal users, most common concern is transference risk - "Always worry with the kids."; "Right now we have to plan sex." - Gels and roll - on are messy to apply and often cause skin irritation Injectable users complain about swings in testosterone levels resulting in "crash" before next dose - "I keep crashing two weeks after the injection" - Needle phobia/needle fatigue are common Both transdermal and injection users also want better symptomatic efficacy 40% Other

TLANDO : Physician Market Research Oral Agent is Most Important Attribute for Prescribers 38 QUESTION: What is the most important advantage of TLANDO? 66% 10% 8% 8% 5% 3% No/Low Risk of Good Efficacy Easy Dosing/ Administration Easy/Less Titration Few Side Effects/ Well-tolerated N=212 (All Respondents; URO=54, ENDO=53, PCP=105), TVG conducted market research. Q35a. In your opinion, what is the most important advantage of TLANDO? Oral Agent No Competing TRT Agent Can Offer

TLANDO : Definitive Phlebotomy Study Ex Vivo Conversion Assessment Study objective: To evaluate the extent, if any, of clinically meaningful ex vivo conversion of TU to T in serum blood collection tubes to confirm the reliability of TLANDO data results Study design: Open - label, single dose study (N=12) Blood sampling post 225 mg TU dose: at 3 hr. and 5 hr. post dosing (N=24) Control : Time zero (immediately processed) plasma tubes with EDTA ("PT") Test : Serum separation tubes ("SST") per manufacturer's recommendation - 30 min.) Top - line results: Mean percentage difference and the associated percentage standard deviation post dose of T concentrations measured between SST samples and PT samples are - 1.0% and 9.2%, respectively The difference was not statistically significant (p = 0.91) 39

TLANDO : Ambulatory Blood Pressure Monitoring Study Results Consistent with a Recently Approved Testosterone Replacement Therapy Study objective: To characterize blood pressure effects of TLANDO for appropriate FDA regulatory action, including Risk Evaluation and Mitigation Strategy ("REMS") beyond labeling Study design (NCT03868059): Open - label, single - arm study in male hypogonadal subjects 144 subjects enrolled, 138 subjects received at least one dose of study drug, 126 subjects completed the study with 118 subjects having evaluable ABPM data at both baseline and end of study Four months of treatment with TLANDO, 225 mg BID 24 - hour blood pressure measurements taken at baseline and at the end of the study Top - line results: 40 Parameter Mean Change, mm Hg (95% CI) 24 - hour SBP 3.82 ( 1.69 , 5.96 ) 24 - h our DBP 1.20 ( 0.31, 2.08 )

High PTB Medical Costs 12% of all US pregnancies 1 (475 - 500K) result in PTB (< 37 weeks) - a leading cause of neonatal mortality and morbidity First year medical costs for PTB infants are ~ 10x higher than for full term infants 2 28% of preterm births are to women with histories of early delivery 42 $26 Billion Economic Impact 3 1. CDC (2010) 2. J. Maternal - Fetal and Neonatal Medicine, Dec. 2006, 19(12), 773 - 782 3 . Institute of Medicine of the National Academies. Jul.200

LPCN 1107: Prevention of Preterm Birth (PTB) United States Market Landscape $1B Market Opportunity 3 December 31, 2017 HPC TRx 4 Makena 1 50% Off Guidance 2 30% Compounded 17 - HPC 20% 117% 1. Amag estimates Makena market share based on distributor dispensing data and all other market share based on physician market resea rc h data conducted by AMAG. 2. Off guidance represents patients treated outside of guidance of Society for Maternal Fetal Medicine, including patients tr eat ed with unapproved therapies and untreated patients. 3. Based on 140,000 patients, >16 injections/patient and net revenue of ~$425 - $450/injection. 4. IMS data 5. Annualized September 30, 2018 data 43 2% 0 10000 20000 30000 40000 50000 60000 70000 80000 90000 100000 2016 2017 2018 TRx 44,220 95,935 94,287 5

LPCN 1107: First Oral PTB Candidate 44 Characteristics of the Only Approved Product Options for PTB IM HPC, Makena : 20 - 25% patients below reported better efficacy HPC level threshold Total of 18 - 22 injections - Injection location: Upper - outer quadrant of the gluteus maximus - Weekly visit to/by health care provider - ~35% of patients experienced injection site pain during clinical trial - ~17% of patients reported site swelling - much greater than placebo during clinical trial Makena 21 gauge needle SubQ HPC, Makena : 20 - 25% patients below reported better efficacy HPC level threshold Total of 18 - 22 injections - Approved February 14, 2018 - Auto injector - ready to use device - Injection location: Upper back of the arm - Weekly visit to/by health care provider - 37.3% of subjects identified injection site pain as a treatment emergent adverse event compared to only 8.2% of subjects in the IM arm

LPCN 1107 - Oral HPC Potential for superior efficacy with Phase 3 target dose No patient discomfort upon administration Steady state achieved in 7 days Orphan drug designation - Major contribution to patient care Next steps: - Explore partnering opportunities LPCN 1107: First Oral PTB Candidate 45 Addresses Unmet Need

LPCN 1107: Economic Impact Potential Lower PTB Rate - US and Resulting Savings Assuming 4.3% lower PTB rate relative to Makena ~6000 fewer annual PTBs Estimated annual cost saving in ~$310M 46 : Assuming 100% of 140,000 eligible US population treated : Assuming ~$51,600 medical costs/PTB

LPCN 1107: First Oral PTB Candidate First Oral HPC for Prevention of Recurrent PTB Preferred route - of - administration is oral Strong Exclusivity Position Orphan Drug Designation Technology/IP protection Potential for Superior Efficacy Fewer PTB babies with significant healthcare cost savings Strong Pharmaco - Economic Justification Minimize travel related cost/time and healthcare provider cost/time Premium pricing potential to generic IM injections 47 Commercial Outlook/Drivers

LPCN 1107: HPC PK - PD Correlation 48 HPC Concentration and PTB Rate with IM HPC, Makena 1 N=315 1. Caritis et al., Am J Obstet Gynecol. 2014 (N=315 subjects) 2. C trough ; C avg for IM Makena Lower % PTB rate can be expected with daily C avg 2 HPC levels 8.2 ng/mL 46.3% 27.0% 29.6% 31.3%

LPCN 1107: Dose Finding Study Design Open - label, four - period, four - treatment study 12 healthy pregnant women - Ages 18 - 35 years; 16 - 18 weeks gestation All subjects received all four treatments 49 PK Study: Oral LPCN 1107 vs IM HPC, Makena Treatment D 250mg Weekly Treatment C 800mg BID Treatment B 600mg BID Treatment A 400mg BID IM HPC, Makena LPCN 1107, Oral HPC Multiple dose: 5 weeks Multiple doses for 8 days

LPCN 1107: Dose - Finding PK Study Results 1 50 Oral LPCN 1107 vs IM HPC, Makena 1. PK results obtained post 8 days of BID dosing for LPCN 1107 and post 5 weeks for weekly IM HPC, Makena Lower reported PTB rate threshold HPC levels below 8.2 ng/mL: - Target LPCN 1107 Phase 3 dose was 0% vs 20% subjects using IM HPC Makena per label Average HPC levels at target LPCN 1107 Phase 3 dose - ~ 3x greater than the comparator, IM HPC, Makena Target Phase 3 dose 0 10 20 30 40 50 60 0 100 200 300 400 500 600 700 800 900 1000 Cavg(0 - 24/ 0 - 168) (ng/mL) BID Dose (mg) IM 250 mg Oral 400 mg Oral 600 mg Oral 800 mg Weekly

LPCN 1107: Advancing to Phase 3 Readiness Phase 3 Special Protocol Assessment - Progress Concurrence with FDA to date: - Study Design Elements Single Phase 3 study Open label, active comparator, two parallel arms (1:1 randomization) General inclusion and exclusion criteria and treatment duration LPCN 1107 dose of 800 mg BID - Endpoints and Analysis Primary endpoint of proportion of PTB < 37 weeks Non - inferiority margin of 7% Secondary endpoint: Neonatal mortality and morbidity composite index Interim analysis with ability to resize the study - Study size: 500 to 1000 subjects per arm Open Items - Data from food effect study to inform dosing instructions - Align on approach to fulfill infant follow up data requirement Next Steps - Continue interactions with FDA on Phase 3 protocol via Special Protocol Assessment - Conduct Food/Fat Effect Study in preparation of Phase 3 study 51